ARMS2/HTRA1 is an important risk factor for identifying eyes likely to experience fast lesion progression.

Clinical trials show Izervay can slow disease progression with as few as six monthly doses.

The metrics could lead to future clinical trials that better characterize both the natural history of the disease as well as early treatment response, the authors suggest.

Study finds GA patients with a reabsorbed PED have significant visual deficits and may not benefit from new treatments aimed at inhibiting the complement system, as the mechanism is different.

The measurement was comparable to that shown on FAF in this study. Dispersion pattern and baseline lesion size may also predict enlargement rate.